857371 | VU0359595

(1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}propan-2-yl)-2-phenylcyclopropanecarboxamide


Powder

Size SKU Packaging Price
1mg 857371P-1mg 857371P-1mg 1 x 1mg $137.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
Please select an option above.
${sku} - ${concentration}

VU0359595

VU0359595

(1R,2R)-N-([S]-1-{4-[5-bromo-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl]piperidin-1-yl}propan-2-yl)-2-phenylcyclopropanecarboxamide

VU0359595 has been shown to selectively inhibit the PLD1 isoform at nM levels (see data below).
 
Hygroscopic
Yes
Light Sensitive
No
Molecular Formula
C25H29BrN4O2
Percent Composition
C 60.36%, H 5.88%, Br 16.06%, N 11.26%, O 6.43%
Purity
>99%
Stability
1 Years
Storage Temperature
-20°C
CAS Number
1246303-14-9
CAS Registry Number is a Registered Trademark of the American Chemical Society
Molecular Weight
497.427
Exact Mass
496.147
Synonyms
<p>EVJVU0359595</p>
Bruntz, R.C., H.E. Taylor, C.W. Lindsley, and H.A. Brown. (2013). Phospholipase D2 mediates survival signaling through direct regulation of Akt in glioblastoma cells. J Biol Chem [PubMed] Lewis, J.A., Scott, S.A., Lavieri, R., Buck, J.R., Selvy, P.E., Stoops, S.L., Armstrong, M.D., Brown, H.A., and C.W. Lindsley. (2009) Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I. Impact of alternative halogenated privileged structures for PLD1 specificity. Bioorganic and Medicinal Chemistry Letters. 19, 1916-1920. [PubMed]